Канал: founders in biotech

The Rationale for Selective NKCC1 Inhibition in Neurodevelopmental Disorders #biotech

The Rationale for Selective NKCC1 Inhibition in Neurodevelopmental Disorders #biotech

Marco De Vivo on Neuroscience Drug Discovery

Marco De Vivo on Neuroscience Drug Discovery

10 Billion Peptides in Engineered Cells Targeting Protein-Protein Interactions #biotech

10 Billion Peptides in Engineered Cells Targeting Protein-Protein Interactions #biotech

Maria Soloveychik on synthetic biology for discovery of protein interaction modulators

Maria Soloveychik on synthetic biology for discovery of protein interaction modulators

How to measure that a biotech company is on the right path? Momentum and control #biotech

How to measure that a biotech company is on the right path? Momentum and control #biotech

🧬 "Let's take that hypothesis and prove it." #biotech #biotechcompanies #cancerresearch

🧬 "Let's take that hypothesis and prove it." #biotech #biotechcompanies #cancerresearch

🌱 Free the Founders 🌱 #biotech #biotechcompanies

🌱 Free the Founders 🌱 #biotech #biotechcompanies

Christoph Lengauer on building visionary biotech companies

Christoph Lengauer on building visionary biotech companies

Deep dive into business development in biotech with James Lee

Deep dive into business development in biotech with James Lee

James Lee on the vital role of business development for biotech companies

James Lee on the vital role of business development for biotech companies

Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics

Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics

Kiyoshi Takayama on targeting challenging GPCRs using monoclonal antibodies

Kiyoshi Takayama on targeting challenging GPCRs using monoclonal antibodies

David Younger on how synthetic biology helps to identify molecular glues

David Younger on how synthetic biology helps to identify molecular glues

Elaine Hamm on overcoming the “shiny object syndrome” in biotech

Elaine Hamm on overcoming the “shiny object syndrome” in biotech

Deep dive into targeted protein degradation and PROTACs with Alessio Ciulli

Deep dive into targeted protein degradation and PROTACs with Alessio Ciulli

Alessio Ciulli on the next level of small molecules as thrapeutics: PROTACs I founders in biotech

Alessio Ciulli on the next level of small molecules as thrapeutics: PROTACs I founders in biotech

ultradeep chemoproteomics and machine learning for covalent drug discovery by MARK TEBBE

ultradeep chemoproteomics and machine learning for covalent drug discovery by MARK TEBBE

building a mission-driven biotech company by CARLO BERTOZZI | founders in biotech

building a mission-driven biotech company by CARLO BERTOZZI | founders in biotech

About founders in biotech

About founders in biotech